Identification of putative noncanonical driver mutations in patients with essential thrombocythemia

被引:0
作者
Arai, Akihiko [1 ,2 ]
Yoshimitsu, Makoto [1 ,3 ,8 ]
Otsuka, Maki [4 ]
Ito, Yoshikiyo [5 ]
Miyazono, Takayoshi [5 ]
Nakano, Nobuaki [5 ]
Obama, Kosuke [6 ]
Nakashima, Hidetoshi [7 ]
Hanada, Shuichi [4 ]
Owatari, Satsuki [4 ]
Nakamura, Daisuke [3 ]
Tokunaga, Masahito [5 ]
Kamada, Yuhei [3 ]
Utsunomiya, Atae [5 ]
Haraguchi, Koichi [4 ]
Hayashida, Maiko [3 ]
Fujino, Satoshi [4 ]
Odawara, Jun [5 ]
Tabuchi, Tomohisa [5 ]
Suzuki, Shinsuke [3 ]
Hamada, Heiichiro [3 ]
Kawamoto, Yoshiko [1 ]
Uchida, Yuichiro [1 ]
Hachiman, Miho [1 ]
Ishitsuka, Kenji [1 ,3 ]
机构
[1] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Hematol & Rheumatol, Kagoshima, Japan
[2] Kagoshima City Hosp, Dept Hematol & Rheumatol, Kagoshima, Japan
[3] Kagoshima Univ Hosp, Dept Hematol & Rheumatol, Kagoshima, Japan
[4] Natl Hosp Org Kagoshima Med Ctr, Dept Hematol, Kagoshima, Japan
[5] Imamura Gen Hosp, Dept Hematol, Kagoshima, Japan
[6] Imakiire Gen Hosp, Dept Hematol, Kagoshima, Japan
[7] Ikeda Hosp, Dept Hematol, Kanoya, Japan
[8] Kagoshima Univ, Dept Hematol & Rheumatol, Grad School Med & Dent Sci, 8-35-1 Sakuragaoka, Kagoshima 8908544, Japan
关键词
essential thrombocythemia; germline mutation; noncanonical driver mutation; triple-negative ET; SPLICE DONOR MUTATION; MPL; CLASSIFICATION; CALRETICULIN; PHENOTYPE;
D O I
10.1111/ejh.13945
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Essential thrombocythemia (ET) cases without canonical JAK2, CALR, or MPL mutations, that is, triple-negative (TN) ET, have been found in 10%-20% of ET cases. Owing to the limited number of TN ET cases, its clinical significance remains unclear. This study evaluated TN ET's clinical characteristics and identified novel driver mutations. Among 119 patients with ET, 20 (16.8%) had no canonical JAK2/CALR/MPL mutations. Patients with TN ET tended to be younger and had lower white blood cell counts and lactate dehydrogenase values. We identified putative driver mutations in 7 (35%): MPL S204P, MPL L265F, JAK2 R683G, and JAK2 T875N were previously reported as candidate driver mutations in ET. Moreover, we identified a THPO splicing site mutation, MPL*636Wext*12, and MPL E237K. Four of the seven identified driver mutations were germline. Functional studies on MPL*636Wext*12 and MPL E237K revealed that they are gain-of-function mutants that increase MPL signaling and confer thrombopoietin hypersensitivity with very low efficiency. Patients with TN ET tended to be younger, although this was thought to be due to the inclusion of germline mutations, hereditary thrombocytosis. Accumulating the genetic and clinical characteristics of noncanonical mutations may help future clinical interventions in TN ET and hereditary thrombocytosis.
引用
收藏
页码:639 / 647
页数:9
相关论文
共 50 条
[41]   Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up [J].
Senin, Alicia ;
Fernandez-Rodriguez, Concepcion ;
Bellosillo, Beatriz ;
Camacho, Laura ;
Longaron, Raquel ;
Angona, Anna ;
Besses, Carles ;
Alvarez-Larran, Alberto .
ANNALS OF HEMATOLOGY, 2018, 97 (03) :443-451
[42]   Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up [J].
Alicia Senín ;
Concepción Fernández-Rodríguez ;
Beatriz Bellosillo ;
Laura Camacho ;
Raquel Longarón ;
Anna Angona ;
Carles Besses ;
Alberto Álvarez-Larrán .
Annals of Hematology, 2018, 97 :443-451
[43]   A risk of essential thrombocythemia in carriers of constitutional CHEK2 gene mutations [J].
Janiszewska, Hanna ;
Bak, Aneta ;
Pilarska, Maria ;
Heise, Marta ;
Junkiert-Czarnecka, Anna ;
Kuliszkiewicz-Janus, Malgorzata ;
Calbecka, Malgorzata ;
Jazwiec, Bozena ;
Wolowiec, Dariusz ;
Kuliczkowski, Kazimierz ;
Haus, Olga .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (03) :366-370
[44]   Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia [J].
Laguna, MS ;
Kornblihtt, LI ;
Marta, RF ;
Michiels, JJ ;
Molinas, FC .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2000, 6 (03) :157-161
[45]   Interferon therapy for pregnant patients with essential thrombocythemia in Japan [J].
Edahiro, Yoko ;
Yasuda, Hajime ;
Gotoh, Akihiko ;
Morishita, Soji ;
Suzuki, Toshifumi ;
Takeda, Jun ;
Ando, Jun ;
Tsutsui, Miyuki ;
Itakura, Atsuo ;
Komatsu, Norio .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (01) :106-111
[46]   Inhibitors of the blood coagulation process in patients with essential thrombocythemia [J].
Ziolkowska, Katarzyna ;
Boinska, Joanna ;
Gadomska, Grazyna ;
Wieczor, Radoslaw ;
Rosc, Danuta .
BLOOD COAGULATION & FIBRINOLYSIS, 2020, 31 (03) :219-224
[47]   Treatment of symptomatic patients with essential thrombocythemia: Effectiveness of anagrelide [J].
Cacciola, RR ;
Cipolla, A ;
Di Francesco, E ;
Giustolisi, R ;
Cacciola, E .
AMERICAN JOURNAL OF HEMATOLOGY, 2005, 80 (01) :81-83
[48]   Management of patients with essential thrombocythemia: current concepts and perspectives [J].
Briere, J ;
Guilmin, F .
PATHOLOGIE BIOLOGIE, 2001, 49 (02) :178-183
[49]   Clinical Characteristics and Management of Cerebral Venous Sinus Thrombosis in Patients with Essential Thrombocythemia [J].
Jiao, Lidong ;
Huang, Xiaoqin ;
Fan, Chunqiu ;
Zhao, Hong ;
Li, Zhen ;
Shen, Huixin ;
Chen, Jian ;
Duan, Jiangang .
NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2021, 17 :1195-1206
[50]   Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera [J].
Reikvam, H. ;
Tiu, R. V. .
LEUKEMIA, 2012, 26 (04) :563-571